The Exit Story in Women’s Health Was Hiding in Plain Sight
Blog Posts
Posted by Bowdoin on August 30, 2026
The Exit Story in Women’s Health Was Hiding in Plain Sight
Katelyn Marini, Partner, The Bowdoin Group | August 2026
For years, women’s health has carried a familiar question from investors: Sounds important, where are the exits? Fair enough.
It turns out the exits were there. They were just filed under diagnostics, oncology, devices, and biopharma instead of “women’s health.” A bit of a spreadsheet problem for a category with a very real $100 billion-plus outcome story.
A new analysis from AOA Dx identified more than $100 billion in realized exit value across women’s health since 2000, including 27 billion-dollar exits. Nearly half occurred in the past five years. And 91% were M&A, not IPOs, which isn’t a red flag, rather shows how durable healthcare businesses tend to exit.
So, the question is no longer whether women’s health can create value.
The better question is: where will the next value be built, and does the company have the leadership to build it?
A Working Business Model in Women’s Health
Progyny’s Q2 results are a useful reminder of what real scale looks like: $350.5 million in quarterly revenue, $89.3 million in gross profit, and $62.1 million in adjusted EBITDA. Its employer-sponsored fertility and family-building model is working because it translated a major care need into something employers and health plans can understand, buy, and measure. That is meaningful validation for women’s health. It is also a useful distinction.
Progyny did not win simply because it serves women. It won because it built a business around clinical outcomes, access, cost management, and a clear economic buyer.
The next generation of women’s health companies will need to do the same.
The Capital Is Still Concentrated
A Kearney analysis of more than 2,000 private deals found that roughly $34 billion has flowed into women’s health since 2020. About $21 billion of that went to women specific conditions, including fertility and reproductive health.
That leaves approximately $13 billion invested in conditions that disproportionately affect women but have not always been treated as women’s health opportunities: cardiovascular disease, autoimmune disorders, Alzheimer’s, mental health, and more.
This is not an argument that fertility is overbuilt. It is an argument that the category has been narrowly defined.
The whitespace is real. So is the work required to turn it into a business.
The Talent Question Is Getting More Interesting
As companies move beyond the most established lanes, they need more than people with a women’s health label on their résumé.
They need leaders who can connect the dots between a distinct clinical reality and a viable healthcare business: evidence generation, reimbursement, product, partnerships, care delivery, and commercial adoption.
That combination is scarce because the market has historically treated these as separate disciplines. A cardiovascular operator may understand the disease state but not the lived experience or diagnostic gap facing women. A women’s health leader may understand the patient and market but not the complex clinical, access, or commercial mechanics of a new therapeutic category.
The strongest teams will bridge both.
For executives, that means pressure-testing whether the leadership team was built for the company you are becoming, not just the science or product you started with.
For investors, it means looking beyond the women’s health tag. Is this a meaningful unmet need with a credible route to evidence, reimbursement, adoption, and scale? And does the team know how to navigate all four?
Because capital can recognize an opportunity. Leadership is what turns it into an enduring company.
P.S. If you are building or evaluating a women’s-health company outside the obvious lanes, I’d be happy to compare notes on the leadership questions that tend to surface next.